

Sudubrilimab

| | |
|-----------|---|
| Cat. No.: | HY-P99963 |
| Target: | PD-1/PD-L1 |
| Pathway: | Immunology/Inflammation |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

Description

Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF- β 1 receptor α ectodomain (TGFB2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF- β bioactivity in the immunosuppressive tumor microenvironment^[1].

REFERENCES

[1]. Gao ZZ, et, al. Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFB2-ECD fusion protein. Protein Expr Purif. 2022 Jan;189:105973.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA